30197-51-4 Usage
Uses
Used in Organic Synthesis:
3-HYDROXY-4-(N,N-DIMETHYLAMINO)-TETRAHYDROFURAN is used as a building block for the synthesis of various pharmaceutical and biologically active compounds. Its unique structural features and properties contribute to the development of new organic compounds with potential applications in different fields.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 3-HYDROXY-4-(N,N-DIMETHYLAMINO)-TETRAHYDROFURAN is utilized as a key intermediate in the development of new drugs. Its potential applications in the synthesis of biologically active compounds make it a compound of interest for medicinal chemistry and drug discovery.
Used in Medicinal Chemistry:
3-HYDROXY-4-(N,N-DIMETHYLAMINO)-TETRAHYDROFURAN is employed in medicinal chemistry for the exploration of its biological activities. Its interesting and potentially valuable biological properties make it a promising candidate for further research and development in the field of drug discovery.
Used in Drug Discovery:
In the realm of drug discovery, 3-HYDROXY-4-(N,N-DIMETHYLAMINO)-TETRAHYDROFURAN is used for identifying and developing new therapeutic agents. Its unique structural features and biological activities hold promise for the creation of innovative pharmaceuticals to address various health challenges.
Check Digit Verification of cas no
The CAS Registry Mumber 30197-51-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,0,1,9 and 7 respectively; the second part has 2 digits, 5 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 30197-51:
(7*3)+(6*0)+(5*1)+(4*9)+(3*7)+(2*5)+(1*1)=94
94 % 10 = 4
So 30197-51-4 is a valid CAS Registry Number.
30197-51-4Relevant academic research and scientific papers
Cycloalkyl and heterocycloalkyl inhibitors as well as preparation method and application thereof
-
Paragraph 0295-0298, (2021/04/26)
The invention relates to cycloalkyl and heterocycloalkyl inhibitors as well as a preparation method and application thereof. Specifically, the compounds disclosed by the invention have a structure as shown in a formula (I). The invention also discloses a preparation method of the compounds and application of the compounds as KRASG12C inhibitors. The compounds have a good selective inhibition effect on KRASG12C, and have better pharmacodynamic and pharmacokinetic properties and lower toxic and side effects.
